Zydus Lifesciences Ltd Share Price – NSE /  BSE

Pharmaceuticals, Mid Cap

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Niacin Extended-Release Tablets USP, 500 mg, 750 mg, and 1,000 mg (Niaspan? Extended-Release Tablets, 500 mg, 750 mg, and 1,000 mg).

Niacin is indicated to reduce elevated total cholesterol (TC), LDL cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase HDL cholesterol (HDL-C) in patients with primary hyperlipidaemia and mixed dyslipidaemia. It is also indicated to reduce the risk of recurrent myocardial infarction in patients with a history of myocardial infarction and hyperlipidaemia and to reduce TG in adult patients with severe hypertriglyceridemia. Niacin-Extended-Release tablets will be produced at the Group's manufacturing site at Moraiya, Ahmedabad.

Niacin-Extended-Release tablets had annual sales of USD 5.5 mn in the United States (IQVIA MAT February 2025).

Powered by Capital Market - Live News

The approved medication is indicated for the treatment of patients with primary hyperlipidemia and mixed dyslipidemia. It helps reduce elevated levels of total cholesterol (TC), LDL-C, apolipoprotein B (Apo B), and triglycerides (TG), while increasing HDL-C. It is also used to reduce the risk of recurrent myocardial infarction in patients with a prior history of heart attack and hyperlipidemia and to treat adults with severe hypertriglyceridemia.

According to IQVIA MAT (February 2025), the annual sales of Niacin Extended-Release tablets in the U.S. market were estimated at $5.5 million. With this latest approval, Zydus has now secured 425 product approvals and has filed a total of 492 Abbreviated New Drug Applications (ANDAs) since initiating the filing process in FY 2003?04.

Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The company reported a 29.62% jump in consolidated net profit of Rs 1,023.5 crore in Q3 FY25 compared with Rs 789.6 crore in Q3 FY24. Revenue from operations increased 16.96% YoY to Rs 5,269.1 crore during the quarter.

Powered by Capital Market - Live News

Zydus Lifesciences has signed the share purchase agreement to acquire 75.4% of the share capital of Amplitude Surgical SA at a price of ?6.25 per Amplitude share from PAI Partners, Olivier Jallabert and other managers of Amplitude, which together with the two share purchase agreements already signed on 11 March 2025 with two minority shareholders represent 85.6% of the share capital of Amplitude.

The transaction is expected to close by Q3 2025.  

Founded in 1997 in Valence, France, Amplitude Surgical is a leading French player in the global market for surgical technologies for lower limb orthopaedics. Amplitude Surgical develops and markets high end products for orthopaedic surgery, covering the main pathologies affecting the hip and knee.

Powered by Capital Market - Live News

The approved medication is indicated for the treatment of patients with primary hyperlipidemia and mixed dyslipidemia. It helps reduce elevated levels of total cholesterol (TC), LDL-C, apolipoprotein B (Apo B), and triglycerides (TG), while increasing HDL-C. It is also used to reduce the risk of recurrent myocardial infarction in patients with a prior history of heart attack and hyperlipidemia and to treat adults with severe hypertriglyceridemia.

According to IQVIA MAT (February 2025), the annual sales of Niacin Extended-Release tablets in the U.S. market were estimated at $5.5 million. With this latest approval, Zydus has now secured 425 product approvals and has filed a total of 492 Abbreviated New Drug Applications (ANDAs) since initiating the filing process in FY 2003?04.

Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The company reported a 29.62% jump in consolidated net profit of Rs 1,023.5 crore in Q3 FY25 compared with Rs 789.6 crore in Q3 FY24. Revenue from operations increased 16.96% YoY to Rs 5,269.1 crore during the quarter.

Powered by Capital Market - Live News

Zydus Lifesciences has signed the share purchase agreement to acquire 75.4% of the share capital of Amplitude Surgical SA at a price of ?6.25 per Amplitude share from PAI Partners, Olivier Jallabert and other managers of Amplitude, which together with the two share purchase agreements already signed on 11 March 2025 with two minority shareholders represent 85.6% of the share capital of Amplitude.

The transaction is expected to close by Q3 2025.  

Founded in 1997 in Valence, France, Amplitude Surgical is a leading French player in the global market for surgical technologies for lower limb orthopaedics. Amplitude Surgical develops and markets high end products for orthopaedic surgery, covering the main pathologies affecting the hip and knee.

Powered by Capital Market - Live News

Zydus Lifesciences announced that the USFDA conducted a surveillance inspection at the group's API Unit, located at Dabhasa in Gujarat. The inspection was conducted from April 21st to 25th, 2025.

The inspection concluded with 6 observations and none of them were related to Data Integrity. The company is confident to address the observations expeditiously.

Powered by Capital Market - Live News

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Niacin Extended-Release Tablets USP, 500 mg, 750 mg, and 1,000 mg (Niaspan? Extended-Release Tablets, 500 mg, 750 mg, and 1,000 mg).

Niacin is indicated to reduce elevated total cholesterol (TC), LDL cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase HDL cholesterol (HDL-C) in patients with primary hyperlipidaemia and mixed dyslipidaemia. It is also indicated to reduce the risk of recurrent myocardial infarction in patients with a history of myocardial infarction and hyperlipidaemia and to reduce TG in adult patients with severe hypertriglyceridemia. Niacin-Extended-Release tablets will be produced at the Group's manufacturing site at Moraiya, Ahmedabad.

Niacin-Extended-Release tablets had annual sales of USD 5.5 mn in the United States (IQVIA MAT February 2025).

Powered by Capital Market - Live News

The approved medication is indicated for the treatment of patients with primary hyperlipidemia and mixed dyslipidemia. It helps reduce elevated levels of total cholesterol (TC), LDL-C, apolipoprotein B (Apo B), and triglycerides (TG), while increasing HDL-C. It is also used to reduce the risk of recurrent myocardial infarction in patients with a prior history of heart attack and hyperlipidemia and to treat adults with severe hypertriglyceridemia.

According to IQVIA MAT (February 2025), the annual sales of Niacin Extended-Release tablets in the U.S. market were estimated at $5.5 million. With this latest approval, Zydus has now secured 425 product approvals and has filed a total of 492 Abbreviated New Drug Applications (ANDAs) since initiating the filing process in FY 2003?04.

Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The company reported a 29.62% jump in consolidated net profit of Rs 1,023.5 crore in Q3 FY25 compared with Rs 789.6 crore in Q3 FY24. Revenue from operations increased 16.96% YoY to Rs 5,269.1 crore during the quarter.

Powered by Capital Market - Live News

Zydus Lifesciences has signed the share purchase agreement to acquire 75.4% of the share capital of Amplitude Surgical SA at a price of ?6.25 per Amplitude share from PAI Partners, Olivier Jallabert and other managers of Amplitude, which together with the two share purchase agreements already signed on 11 March 2025 with two minority shareholders represent 85.6% of the share capital of Amplitude.

The transaction is expected to close by Q3 2025.  

Founded in 1997 in Valence, France, Amplitude Surgical is a leading French player in the global market for surgical technologies for lower limb orthopaedics. Amplitude Surgical develops and markets high end products for orthopaedic surgery, covering the main pathologies affecting the hip and knee.

Powered by Capital Market - Live News

The approved medication is indicated for the treatment of patients with primary hyperlipidemia and mixed dyslipidemia. It helps reduce elevated levels of total cholesterol (TC), LDL-C, apolipoprotein B (Apo B), and triglycerides (TG), while increasing HDL-C. It is also used to reduce the risk of recurrent myocardial infarction in patients with a prior history of heart attack and hyperlipidemia and to treat adults with severe hypertriglyceridemia.

According to IQVIA MAT (February 2025), the annual sales of Niacin Extended-Release tablets in the U.S. market were estimated at $5.5 million. With this latest approval, Zydus has now secured 425 product approvals and has filed a total of 492 Abbreviated New Drug Applications (ANDAs) since initiating the filing process in FY 2003?04.

Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

The company reported a 29.62% jump in consolidated net profit of Rs 1,023.5 crore in Q3 FY25 compared with Rs 789.6 crore in Q3 FY24. Revenue from operations increased 16.96% YoY to Rs 5,269.1 crore during the quarter.

Powered by Capital Market - Live News

Zydus Lifesciences has signed the share purchase agreement to acquire 75.4% of the share capital of Amplitude Surgical SA at a price of ?6.25 per Amplitude share from PAI Partners, Olivier Jallabert and other managers of Amplitude, which together with the two share purchase agreements already signed on 11 March 2025 with two minority shareholders represent 85.6% of the share capital of Amplitude.

The transaction is expected to close by Q3 2025.  

Founded in 1997 in Valence, France, Amplitude Surgical is a leading French player in the global market for surgical technologies for lower limb orthopaedics. Amplitude Surgical develops and markets high end products for orthopaedic surgery, covering the main pathologies affecting the hip and knee.

Powered by Capital Market - Live News

Zydus Lifesciences announced that the USFDA conducted a surveillance inspection at the group's API Unit, located at Dabhasa in Gujarat. The inspection was conducted from April 21st to 25th, 2025.

The inspection concluded with 6 observations and none of them were related to Data Integrity. The company is confident to address the observations expeditiously.

Powered by Capital Market - Live News